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Abstract
The proteasome inhibitor bortezomib (Velcade) is prescribed for the treatment of multiple myeloma. Clinically achievable
concentrations of bortezomib cause less than 85% inhibition of the chymotrypsin-like activity of the proteasome, but little
attention has been paid as to whether in vitro studies are representative of this level of inhibition. Patients receive
bortezomib as an intravenous or subcutaneous bolus injection, resulting in maximum proteasome inhibition within one
hour followed by a gradual recovery of activity. In contrast, most in vitro studies use continuous treatment so that activity
never recovers. Replacing continuous treatment with 1 h-pulse treatment increases differences in sensitivity in a panel of 7
multiple myeloma cell lines from 5.3-fold to 18-fold, and reveals that the more sensitive cell lines undergo apoptosis at
faster rates. Clinically achievable inhibition of active sites was sufficient to induce cytotoxicity only in one cell line. At
concentrations of bortezomib that produced similar inhibition of peptidase activities a different extent of inhibition of
protein degradation was observed, providing an explanation for the differential sensitivity. The amount of protein degraded
per number of active proteasomes correlated with sensitivity to bortezomib. Thus, (i) in vitro studies of proteasome
inhibitors should be conducted at pharmacologically achievable concentrations and duration of treatment; (ii) a similar level
of inhibition of active sites results in a different extent of inhibition of protein breakdown in different cell lines, and hence a
difference in sensitivity.
Citation: Shabaneh TB, Downey SL, Goddard AL, Screen M, Lucas MM, et al. (2013) Molecular Basis of Differential Sensitivity of Myeloma Cells to Clinically
Relevant Bolus Treatment with Bortezomib. PLoS ONE 8(2): e56132. doi:10.1371/journal.pone.0056132
Editor: Susheela Tridandapani, The Ohio State University, United States of America
Received September 30, 2012; Accepted January 5, 2013; Published February 27, 2013
Copyright:  2013 Shabaneh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: These studies were supported by grant R01CA124634 from the NCI, by the American Recovery and Reinvestment Act supplement to this grant, and by
a grant from the Multiple Myeloma Research Foundation (http://www.themmrf.org).The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Alexei.F.Kisselev@Dartmouth.edu
¤a Current address: Torbay Hospital, Newton Road, Torquay, Devon, United Kingdom
¤b Current address: Medical Research Council Toxicology Unit, University of Leicester, Lancaster Road, Leicester, United Kingdom
¤c Current address: Trinity Partners, Waltham, Massachusetts, United States of America
Introduction
The proteasome inhibitor bortezomib (Velcade, PS-341) is
prescribed for the treatment of multiple myeloma and mantle cell
lymphoma. The second proteasome inhibitor, carfilzomib (Ky-
prolis, PR-171) [1], was recently approved by the FDA for the
treatment of relapsing and refractory myeloma. At least four novel
proteasome inhibitors — marizomib (salinosporamide A, NPI-
0052) [2], CEP-18770 [3], MLN-9708 [4], and PR-047 [5]—are
at different stages of clinical development.
Bortezomib is highly cytotoxic to all multiple myeloma cell lines
in vitro [6], but in vivo only ,40% of myeloma patients respond
to this drug given as a single agent [7]. One reason for this
discrepancy may be that in vitro concentrations of bortezomib and
length of exposure to this agent exceed those that can be achieved
in vivo at the maximal tolerated dose (MTD). Most studies of
bortezomib in cell culture have utilized continuous incubation for
24–48 h. In the clinical setting, patients receive intravenous or
subcutaneous bolus injections twice weekly. When bortezomib is
injected intravenously at the MTD, the blood plasma concentra-
tion peaks at 100–200 ng/mL (260–520 nM) 5 minutes after IV
injection followed by rapid decrease [8]. Subcutaneous injection
results in ,10-fold lower maximal concentration, which is
achieved 30 minutes after injection. The maximal concentration
of the drug is maintained for 1–2 h so that total exposure to the
drug (area under the Drug concentration-Time curve) is the same
as after iv administration. Efficacy of the agent does not depend on
the administration route [9].
The primary target of botezomib is the chymotrypsin-like
activity of the proteasome. At the MTD, the mean maximal
inhibition of proteasome in patient’s peripheral blood cells is 73%
after the first dose and up to 83% after subsequent doses [8,10–
13]. This inhibition is achieved within 5–30 min of administration.
The inhibition stays at this level for ,1 h and then slowly
decreases to 0–25% 48–72 hours later [8–11,14]. When bortezo-
mib is administered subcutaneously maximal proteasome inhibi-
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tion in blood is 5% lower than after IV dose and is achieved 2 h
after administration. However, the rate of recovery is slightly
slower and the area under the effect-time curve is the same as after
intravenous administration [9].
Proteasome inhibition inside MM tumors in patients has not
been studied. In a few clinical cases analyzed, inhibition of
proteasome in solid tumor biopsies was found to be the same as in
blood [10,11]; however, inhibition in bone marrow was found to
be half of the inhibition in blood of the same patient [11].
Proteasome inhibition in xenograft tumors in mice was ,1/2 of
the inhibition in blood [15]. Hence we should assume that
inhibition of the proteasome inside myeloma tumors does not
exceed and most likely is even lower than in blood.
The proteasome core has three pairs of active sites for
proteolysis – chymotrypsin-like (ß5), trypsin-like (ß2), and
caspase-like (ß1). Cells and tissues of the immune system, including
multiple myeloma cells, also contain immunoproteasomes, which
express different active-site subunits, i.e., ß5i, ß2i, and ß1i.
Chymotrypsin-like sites (ß5, ß5i) are the primary targets of
bortezomib, but ß1, ß1i, and ß2i are also inhibited, albeit with
lesser potency, and ß2 is activated [16–18]. Inhibition of the
proteasome in blood of patients is evaluated based on cumulative
inhibition of ß5 and ß5i (chymotrypsin-like) sites.
Although the chymotrypsin-like sites are the most important in
protein degradation, our earlier work has indicated that specific
inhibition of these sites is not sufficient to block protein
breakdown, and co-inhibition of either caspase-like or trypsin-like
sites is required [17]. This raises the question of how much protein
degradation is blocked at clinically achievable levels of proteasome
inhibition, when chymotrypsin-likes sites are inhibited by not more
than 85%. Inhibition of caspase-like sites and trypsin-like sites has
not been reported in clinical samples; but, based on data in
multiple myeloma cell lines, we predict that, at the MTD of
bortezomib, caspase-like activity is partially inhibited and trypsin-
like sites may even be activated. Effects of bortezomib on protein
degradation in multiple myeloma cells have not been reported in
the literature.
It has been suggested that myeloma cells are particularly
sensitive to proteasome inhibitors due to their high ratio of
proteasome workload to proteasome expression levels (the ‘‘load/
capacity’’ hypothesis) [19]. Myeloma cells produce large amounts
of immunoglobulins, complex four-chain molecules with several
inter- and intra-chain disulfide bridges. Polypeptide chains that fail
to fold or assemble have to be degraded via the endoplasmic
reticulum (ER)-degradation pathway, imposing a heavy load on
the proteasomes of these cells. Consistent with this hypothesis,
increased production of immunoglobulins sensitizes myeloma cells
to proteasome inhibitors [20].
In this study, we have compared the effects of continuous
bortezomib treatment with a 1-h pulse on a panel of multiple
myeloma cell lines. We observed that this shorter incubation
increased the differences in sensitivity between cell lines. The most
sensitive cell lines underwent apoptosis at clinically achievable
bortezomib concentrations and at faster rates than the least
sensitive ones; the least sensitive lines remained 100% viable under
these conditions. We then found that similar inhibition of active
sites by bortezomib causes stronger inhibition of protein break-
down in sensitive cell lines, potentially explaining their enhanced
sensitivity.
Experimental Procedures
Cell lines, inhibitors and antibodies
NCI-H929 and RPMI-8226 cells were obtained from American
Tissue Culture Collection. KMS-12-BM [21], and KMS-18 [22]
cell lines were provided by Takemi Otsuki (Kawasaki Medical
School, Japan). The MM1.S cell line and its dexamethasone-
resistant derivative MM1.R [23] were provided by Dr. Steven
Rosen (Northwestern University, Chicago, IL). Sensitivity to
dexamethasone was verified with Alamar Blue assay. RPMI-
8226 derived melphalan-resistant LR5 cells [24] were provided by
Dr. William Dalton (Moffit Cancer Center, Tampa, FL). All cell
lines were cultured in RPMI-1640 media supplemented with 10%
fetal bovine serum (FBS), penicillin (100 mg/ml), streptomycin
(100 units/ml), and anti-mycoplasma antibiotic plasmocin
(2.5 mg/mL, Invivogen, San Diego CA). Bortezomib was pur-
chased from Milleneum (Cambridge, MA) through Dartmouth-
Hitchcock Medical Center pharmacy (experiments on Fig. 1, 2C)
or LC laboratories (all other data). Drug from both sources had the
same effect on cell viability in experiments shown in Fig. 1B.
Benzyloxycarbonyl-Leu-Leu-Leu-epoxyketone (ZL3ek) was syn-
thesized as described [25]. Poly-ADP-ribose polymerase (PARP)
antibodies were from Cell Signaling (catalog # 9542) and actin
antibodies were from Abcam (catalog # AB3280).
Cell viability, apoptosis, total protein and proteasome
assays
Viable cells were assessed with Alamar Blue (AbD Serotec or
Invitrogen) as described [26]. Annexin V staining was performed
using a Guava Nexin kit followed by analysis on a Guava mini flow
cytometer. Caspase-3 and -7 activities were measured in extracts
of cells lysed with digitonin lysis buffer (DLB, 50 mM Tris,
pH 7.5, 250 mM sucrose, 5 mM MgCl2, 1 mM ATP, 0.5 mM
EDTA, 1 mM DTT, 0.025% digitonin) using Ac-DEVD-7-
amido-4-methylcoumarinamide (amc) substrate as described
[26]. For western blot analysis cells were lysed in whole cell lysis
buffer (50 mM Tris, pH 7.5, 10% glycerol, 5 mM MgCl2, 1 mM
EDTA, and 0.5% CHAPS). Total protein was determined using
Pierce 660 nM Protein assay. The activity of each proteasome
active site in cells was determined using site-specific luminogenic
substrates Suc-LLVY-amino-luciferine (aLuc), Z-nLPnLD-aLuc,
and Boc-LRR-aLuc (ProteasomeGlo assay, Promega). The spec-
ificity of this assay in multiple myeloma cells has been established
previously [26,27].
Measurement of protein synthesis and degradation rates
56105 cells (three replicates for each condition) were seeded in
suspension cultures in RPMI-1640 media containing half-normal
concentration of Leu and supplemented with 10 mCi/mL [3H]Leu
and 10% dialyzed FBS. For synthesis measurements, 200 mL
aliquots of cultures were withdrawn and mixed with 1/10 volume
of ice-cold 100% trichloroacetic acid (TCA) in pre-cooled tubes.
After 25 min incubation on ice, samples were centrifuged for
15 min at 20,000 g. Pellets of TCA-precipitated proteins were
washed twice with ice-cold acetone, air-dried, and dissolved in
20 mL of 100% TCA. 20 mL of the supernatants from the 10%
TCA precipitation step and 100% TCA-dissolved pellets were
mixed with 250 mL scintillation fluid and counted on a scintillation
plate reader. The amount of incorporated [3H]Leu was calculated
as a percentage of total radioactivity in the culture, and replicates
were averaged and plotted against time. Protein synthesis rates
were calculated from the slopes of the curves. For synthesis of
short-lived proteins, [3H]Leu incorporation was measured over a
Myeloma Sensitivity to Bortezomib
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Figure 1. Comparison of 48-h continuous and a 1-h treatment of multiple myeloma cells with bortezomib. A. Cells were treated with
bortezomib for 48 h, and then assayed for viable cells with the Alamar Blue mitochondrial dye conversion assay. Mock-treated cells served as control.
Values are means6S.E.M of two experiments. B. Cells were treated with bortezomib for 1 h, then cultured in a drug-free media for an additional 47 h
and finally assayed for viable cells with Alamar blue. Values are mean 6 S.E.M of 4–13 measurements. IC50 values are presented in the legend.
doi:10.1371/journal.pone.0056132.g001
Figure 2. Bortezomib-treated multiple myeloma cells undergo apoptosis at different rates. Caspase-3 activity (A) and cleavage of PARP
(B) were measured in extracts of cells treated with bortezomib for 1 h, and then cultured in drug-free media. B. Cleavage of PARP was assessed by
western blotting. C. The % of Annexin V-positive cells was determined by flow cytometry. Cells on the first 3 graphs were analyzed 24 h after the start
of 1-h bortezomib treatment. Values are averages 6 S.E.M of 2–4 independent experiments.
doi:10.1371/journal.pone.0056132.g002
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1-h period. For synthesis of long-lived proteins, [3H]Leu
incorporation was measured over a 16-h period.
To measure the breakdown of short-lived proteins, cultures of
MM cells (56105 cells/ml) were pulse-labeled with 10 mCi/mL
[3H]Leu for 1 h, and then washed 3 times with warm chase media
(RPMI-1640 media containing Leu at 2.56normal concentration
(1 mM)). (Cells were washed four times during optimization of the
protocol; the fourth wash was found to contain background
counts—Table S1.) After washing, each suspension culture was
incubated in the chase media and after 1 h, treated with TCA, and
analyzed by scintillation counting as in the protein synthesis
experiment. The calculations were performed as follows: percent-
age protein breakdown= total dpm in TCA supernatant/(total
dpm in TCA supernatant+total dpm in TCA pellet)6100%.
Replicates were averaged. Treatment with ZL3ek and bortezomib
was performed during pulse labeling. These inhibitors did not
affect protein synthesis rates (Table S2). ZL3ek is an irreversible
epoxyketone inhibitor that forms two stable covalent bonds with
the proteasome catalytic threonine [28] thereby preventing
recovery during the chase.
Long-lived proteins in MM cells were radiolabeled under the
same conditions used for short-lived proteins, except that duration
of labeling was 16 h. Cells were washed three times with chase
media, and incubated in the chase media for 1 h to allow for the
degradation of short-lived proteins. Treatment with ZL3ek
(10 mM) was performed during this 1 h incubation. After an
additional wash with chase media to remove the inhibitor, cells
were resuspended in fresh chase media. Aliquots of culture were
withdrawn at 0, 1, 2 h and treated with TCA as described in
protein synthesis experiments. % Protein degraded was calculated
as (total cpm in the supernatant6100%)/(total cpm in pellet+total
cpm in the supernatant) and plotted against time. The rate of
degradation of long-lived proteins (%/h) was determined as the
slope of resulting linear regression.
Results
Comparison of cytotoxicity following 1 h and 48 h
incubation
In the initial experiment, seven myeloma cell lines were
incubated with bortezomib continuously for 48 h, after which
viable cells were assessed with Alamar Blue (Fig. 1A). All lines were
highly sensitive, with an IC50 between 1.9 and 10.2 nM. When
incubation was shortened to 1 h, followed by a subsequent 47 h
incubation in drug-free media, the IC50 in all cells increased but
the magnitude of the increase varied 15–54-fold, so that the
difference in IC50 across the panel increased to 18-fold, from 28 to
504 nM (Fig. 1B). This 1-h exposure of cells to bortezomib
resembles the brief exposure of cells to the maximal concentration
of the agent when it is administered subcutaneously [9]. The
majority of IC50 values are higher than ,50 nM (20 ng/mL),
which is the maximal concentration of the drug achieved in blood
after subcutaneous administration [9]. The biggest difference in
cytotoxicity was observed upon 1-h treatment with 100 nM
bortezomib, which was highly cytotoxic to NCI-H929 cells but
produced only a slight decrease in the number of viable LR5 and
KMS-12-BM cells. Thus, shortening the treatment time to a more
clinically relevant 1 h reveals larger differences in multiple
myeloma cell sensitivity to bortezomib than previously appreciat-
ed.
In addition, we observed that the sensitive cell lines underwent
apoptosis at faster rates following a 1-h treatment with bortezomib
(Fig. 2). Caspase activation (Fig. 2A) and PARP cleavage (Fig. 2B)
were observed in NCI-H929, MM1.R and MM1.S cells by 6 h,
while it was not detected in KMS-12-BM and KMS-18 cells until
12 h or even 24 h after the treatment, even at the higher
concentrations required to induce apoptosis in these cell lines
(Fig. 2A and B). In RPMI-8226 and LR5 cell lines, only traces of
caspase activity were detected 6 h after treatment. Similar results
were obtained when apoptotic cells were quantified with Annexin
V+ and analyzed by flow cytometry (Fig. 2C).
Clinically achievable proteasome inhibition is not
sufficient to induce apoptosis in the majority of myeloma
cell lines
We next asked whether cytotoxicity is observed upon incubation
with bortezomib at concentrations that result in maximal clinically
achievable levels of proteasome inhibition (i.e., 70–85% inhibition
of the proteasome’s chymotrypsin-like sites). For this purpose,
residual activity of proteolytic sites was measured immediately
after a 1-h incubation with bortezomib and plotted against the
number of viable cells after a further 47-h incubation in drug-free
media (Fig. 3A). 85% inhibition of the chymotrypsin-like sites was
achieved at 33 nM bortezomib in all cell lines. This concentration
is slightly lower than the maximal concentration in blood plasma
of MM patients treated subcutaneously. In the majority of cell
lines little or no reduction of viable cells (Fig. 3A) and caspase
activation (Fig. 2A) was observed at this concentration. The NCI-
H929 cell line was the only exception as a clear reduction in viable
cells was observed as the bortezomib concentration increased from
11 to 33 nM (Fig. 3A). In the majority of cell lines, .95%
inhibition of chymotrypsin-like sites and co-inhibition of caspase-
like sites was needed to reduce the number of viable cells to below
10%. This indicates that most MM cell lines are resistant to
clinically achievable levels of proteasome inhibition.
Differences in recovery of proteasome activity cannot
explain differential sensitivity
We next set out to determine the molecular basis of the
differences in sensitivity to bortezomib. As the levels of proteasome
inhibition in all cell lines were similar, the observed differences in
cell sensitivity to bortezomib cannot be attributed to different cell
permeability of the drug, drug efflux, or a mutation in the
proteasome-binding site.
Theoretically, bortezomib is a reversible inhibitor. Therefore,
another reason for differential sensitivity could be different rates of
recovery of activity after removal of the drug. To determine
whether this is the case, we measured activity of the chymotrypsin
and caspase-like sites at different times following 1-h treatment
with 100 nM bortezomib, a concentration that generated largest
differences in sensitivity (Fig. 3B). During the first six hours, 11–
26% of chymotrypsin-like activity and 24–23% caspase-like
activity recovered. Recovery continued in the cell lines that were
not undergoing apoptosis. This rate of recovery of chymotrypsin-
like activity is similar to the rate of recovery in blood of
bortezomib-treated patients [10,12]. Since the largest differences
are observed at time points after death is initiated in sensitive lines
(NCI-H929, MM1.R, MM1.S), we conclude that the difference in
recovery of activity during drug washout cannot explain all the
differences in sensitivity.
The moderate recovery observed in these experiments could be
due to the synthesis of new proteasomes [29]. We used western
blots to test whether the amount of proteasome subunits increase
in bortezomib-treated RPMI-8226, LR5 and KMS-12-BM cells
but did not observe an increase (Fig. S1). Thus, synthesis of new
proteasome can account for recovery of activity only if inhibited
proteasomes are degraded. It is not known whether inhibited
Myeloma Sensitivity to Bortezomib
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e56132
proteasomes undergo selective degradation. Therefore, the most
likely mechanism of recovery is dissociation of the drug.
Effects of bortezomib on protein breakdown in MM cells
We next tested whether differences in inhibition of protein
turnover could account for differences in sensitivity to bortezomib.
Our earlier studies had established that both chymotrypsin-like
sites and either caspase-like or trypsin-like sites have to be
inhibited to achieve significant inhibition of protein degradation
[17]. The largest differences in sensitivity were observed at
100 nM bortezomib, when caspase-like sites were only partially
inhibited (Fig. 3), suggesting that the ability of proteasomes to
degrade proteins was not completely impaired. Using pulse-chase
experiments to measure overall protein degradation, we found that
23–30% of proteins labeled with [3H]Leu during a 1-h pulse were
degraded during the first hour of the chase (Table 1). Although we
did not determine the composition of this group of proteasome
substrates, we assume that abnormal, misfolded proteins, predom-
inantly immunoglobulin light and/or heavy chains, constitute the
bulk of these short-lived proteins.
To determine the contribution of total proteasome activity to
this process, we used the highly specific proteasome inhibitor
ZL3ek [25] at a concentration that blocks 99% of chymotrypsin-
like activity and at least 80% of the two other proteasome activities
in the majority of cell lines (Table S3). ZL3ek inhibited
degradation up to 63% during the first hour of the chase
Figure 3. One-hour treatment with bortezomib causes similar inhibition of proteasome inside multiple myeloma cells. A. Inhibition of
active sites was measured in cells immediately after 1-h of treatment with bortezomib. Mock-treated cells served as control. An aliquot of cells was
cultured in fresh drug-free media for an additional 48 h, followed by Alamar Blue assay for cell viability. Values are averages6S.E.M of 2 or 3
experiments. The % of viable cells differ from Fig. 1B where they are averages of more repeats. B. Recovery of activity in cells treated for 1 h with
100 nM bortezomib. The first measurement was immediately after removal of bortezomib. Values are averages 6 S.E.M of 2 independent
experiments. Mock-treated cells served as controls. The activity is normalized to cell count at time zero. In NCI-H929, MM1.R and MM1.S cells, no data
is presented at time points beyond 6 h because the number of viable cells decreases rapidly due to cell death (Fig. 2). Western blots analyzing
proteasome amounts are shown on Fig. S1.
doi:10.1371/journal.pone.0056132.g003
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(Table 1). This is similar to the earlier observation that
proteasomes degrade 57% of short-lived proteins in exponentially
growing fibroblasts [30]. Accordingly, we used the ZL3ek-sensitive
fraction of proteins degraded in the first hour as indication of the
total proteasome activity so that we could quantify inhibition of
proteasomal protein degradation by the different treatments.
1 h pre-treatment with 100 nM bortezomib had dramatically
different effects on the degradation of short-lived proteins in
different cell lines. In the most sensitive cell lines (NCI-H929),
where this concentration reduced the viability by 97%, bortezomib
inhibited proteasome-dependent degradation by 56% (Table 1). In
the LR5 cell line, there was only 23% inhibition of proteasome-
dependent protein breakdown and almost no reduction of
viability. Overall there was a very good correlation (r2 = 0.87)
between the inhibition of protein breakdown and the reduction in
number of viable cells (Fig. 4A). Thus, at clinically achievable
levels of active site inhibition, degradation of short-lived proteins
by proteasomes is inhibited by more than 40% in highly sensitive
cell lines but to a lesser extent in resistant cell lines.
These data suggest that the differences in sensitivity can be
explained by different inhibition of protein breakdown. If this is
the case, then 50% or higher inhibition of proteasomal protein
degradation should be observed in resistant cell lines at
concentrations that cause 90% reduction in viable cells. Indeed,
900 nM bortezomib inhibited proteasomal degradation of short-
lived proteins by 86% in KMS-18 cells, by 57% in RPMI-8226
cells and by 48% in LR5 cells, where it reduced viable cells to 12,
11 and 13% respectively. 2.7 mM bortezomib caused 69%
inhibition in KMS-12-BM lines and reduced viable cells to 6%
(Table 1). Therefore, bortezomib needs to block at least 50% of
protein degradation by proteasomes in order to achieve ,85%
reduction of viable cells.
Analysis of load/capacity
The surprising finding that similar inhibition of active sites leads
to different levels of inhibition of protein degradation is consistent
with the load/capacity hypothesis. It postulates that differences in
sensitivity can be explained by differences in the ratio of the
amount of proteins degraded by the proteasome (load) versus the
amount of active proteasomes (capacity) [19]. This hypothesis
predicts that similar occupancy of active sites by an inhibitor
would cause a stronger effect on protein degradation in cells with
higher load/capacity ratio. The variable effect of 100 nM
bortezomib on protein breakdown may indicate that load/
capacity in bortezomib-sensitive NCI-H929, MM1.R and
MM1.S cell lines are higher than in cell lines that are less sensitive
to bortezomib and that bortezomib sensitivity is indeed deter-
mined by load/capacity ratio. This hypothesis was previously
proposed based on the comparison of load/capacity ratios in a
limited number (four) of cell lines, treated continuously with
proteasome inhibitors [19]. The independent data supporting this
hypothesis is that sensitivity of myeloma cells depends on their
level of production of immunoglobulins [20,31–33]. To determine
whether differences in sensitivity to bortezomib in our panel of
seven cell lines can be explained by differences in the load/
capacity we decided to determine the load/capacity in all 7 cell
lines in the panel and correlate it with IC50 after the 1-h treatment.
Table 1. Effect of inhibitors on degradation of short-lived proteins in multiple myeloma cells.
Cell line Total degradation Inhibitor (mM)
Inhibition of Total
Degradation
Inhibition of Proteasomal
Degradation Viable Cells
(%/h) (%) (n) (%) (%)
NCI-H929 30.0 ZL3ek 10 6163 5
bortezomib 0.1 3463 2 55 3
MM1.R 26.3 ZL3ek 10 6064 4
bortezomib 0.1 2961 2 48 32
MM1.S 26.1 ZL3ek 7064 2
bortezomib 0.1 3065 2 43 44
KMS-18 26.3 ZL3ek 10 6264 4
bortezomib 0.1 2364 2 37 77
bortezomib 0.9 5362 3 86 12
RPMI-8226 26.2 ZL3ek 10 6261 3
bortezomib 0.1 1663 2 26 72
bortezomib 0.9 3965 3 57 11
LR5 23.2 ZL3ek 10 7362 2
bortezomib 0.1 1762 4 23 95
bortezomib 0.9 3563 3 48 13
KMS-12-BM 25.7 ZL3ek 10 5464 4
bortezomib 0.1 1661 3 30 95
bortezomib 2.7 3762 4 69 6
Degradation of short-lived proteins was analyzed after 1-h pulse labeling with [3H]Leu followed by 1-h chase. Total degradation was calculated as % of [3H]Leu
incorporated during released in the TCA-soluble fraction during 1 h chase. Treatment with inhibitors was performed during pulse labeling.
% inhibition of degradation (at 1 h) was calculated as [1–(%TCA soluble radioactivity in the presence of inhibitor)/(% TCA soluble in the absence of inhibitor)]6100%.
Inhibition of proteasomal degradation was determined by dividing inhibition by bortezomib by inhibition by ZL3ek.
Values are averages 6 SEM of n independent experiments for inhibition of protein degradation. Data on viable cells are from Fig. 1B, where errors are shown.
doi:10.1371/journal.pone.0056132.t001
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In order to measure load on the proteasomes (i.e., amount of
proteins degraded), it is necessary to determine the amount of
protein degradation and the contribution of proteasome to protein
turnover. Furthermore, because the rate of protein degradation is
normalized to the total amount of radioactivity incorporated in
proteins during the pulse, the differences in the amounts of
[3H]Leu incorporation also have to be accounted for. We found
that the cells differed more than three-fold in amounts of
radioactive Leu incorporated during a 1-h pulse-labeling
(Table 2). The proteasome load was then calculated for each cell
line as the amount of protein synthesized (i.e., amount of [3H]Leu
incorporated)6rate of degradation of short-lived proteins (i.e.,
amount of [3H]Leu released)6percent inhibition of degradation by
ZL3ek (Table 2).
To estimate the relative contribution of long-lived proteins to
proteasome load, we metabolically labeled proteins in NCI-H929
and RPMI-8226 cells for 16 h, allowed degradation of short-lived
proteins to proceed for 1 h, and then analyzed the breakdown for
the subsequent 2 h. The rate of degradation was 5–6% of [3H]Leu
incorporated in proteins, and near complete inhibition of
proteasome led to 50–60% rate decrease (Table 3). Simple
calculations described in have allowed us to estimate that the
contribution of long-lived proteins to the overall load on the
proteasome is 9–10% (Table 3). Therefore, we concluded that
most of the load on proteasome comes from short-lived proteins
and based all comparisons of the load on the degradation of short-
lived proteins.
The proteasome capacity was measured as the amount of
specific, ZL3ek-inhibitable, chymotrypsin-like activity (the other
two activities were proportional to the chymotrypsin-like activity in
all cell lines, not shown) in total cell extract (per number of cells
lysed). Other studies have compared proteasome amounts by
western blotting with antibodies to proteasome subunits [19], but
we believe that measuring activity is a more accurate way to
measure the capacity of active proteasomes, as quantification by
western blot may include inactive proteasomes (e.g., closed gate
form of 20S). Finally, dividing load by capacity gave the load/
capacity ratio, which varied from 0.67 (KMS-12-BM) to 1.29
(NCI-H929). The resulting load/capacity numbers were then
plotted against IC50 for the respective cell lines, with a correlation
of r2 = 0.74 (Fig. 4B). Taken together, these data strongly support a
role of the load/capacity ratio in multiple myeloma sensitivity to
proteasome inhibitors.
Discussions
To our knowledge, this study is the first attempt to investigate
the effect of bortezomib on myeloma cells in vitro under
conditions that resemble in vivo conditions, in which the drug is
given as a bolus injection. This study offers several important and
novel observations. First, shortening treatment to 1 h reveals
greater differences in sensitivity between cell lines than continuous
treatment (Fig. 1). Second, myeloma cells differ in the rates at
which they undergo apoptosis upon bortezomib treatment (Fig. 2).
Third, in the majority of cell lines, clinically achievable inhibition
does not reduce cell viability (Fig. 3). Fourth, similar inhibition of
active sites results in a markedly different inhibition of protein
breakdown in different cell lines (Table 1). Fifth, ,50% inhibition
of proteasomal protein breakdown is needed to reduce cell
viability by 90%.
The observation that myeloma cells do not undergo apoptosis
upon clinically achievable 85% inhibition of the chymotrypsin-like
sites (or perhaps even lower inhibition in the bone marrow [11])
may appear to be contradictory to the 40% response rate to single-
agent bortezomib observed clinically [7,34]. Another paradox is
that cells derived from other cancers are as sensitive to bortezomib
in vitro as myeloma cells [15] but clinically myeloma is the most
bortezomib-responsive malignancy. One possible explanation for
these differences is that myelomas are more sensitive to
proteasome inhibitors when placed in the bone marrow microen-
vironment in vivo [35], suggesting that myeloma cell are sensitized
to bortezomib in vivo by its microenvironment. This sensitization
has not yet been reproduced in vitro as culturing MM cells in the
presence of bone marrow stromal cells either had no effect [36] or
reduced [37] their sensitivity to bortezomib. In culture, increases
in immunoglobulin secretion sensitize myeloma [20,32] and
plasma [33] cells to bortezomib. Conversely, treatment with
cycloheximide to inhibit protein synthesis de-sensitizes them to
proteasome inhibitors [33]. Lower protein synthesis in established
myeloma cell lines may make them less sensitive to bortezomib
compared to MM tumors in vivo. In the future it will be interesting
to determine whether a patient’s response to bortezomib can be
predicted based on the sensitivity of freshly-isolated myeloma cells
to ex vivo pulse treatment with bortezomib.
Correlation between inhibition of protein degradation
and cytotoxicity
The effects of bortezomib on the degradation of short-lived
proteins in multiple myeloma cells have not been reported in the
literature. This study established that, on average, 60% of short-
lived proteins in myeloma cells are degraded by the proteasomes,
consistent with earlier findings in fibroblasts [30]. Inhibiting about
half of the proteasomal protein degradation results in an 85%
decrease in viable cells.
Figure 4. Correlation between load/capacity and sensitivity. A. Plot of viable cells vs. inhibition of protein degradation (from Table 1). B. Plot
of load/capacity (from Table 2) vs. IC50 (from Figure 1).
doi:10.1371/journal.pone.0056132.g004
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Chymotrypsin-like sites have long been considered the most
important sites for protein degradation. However, our earlier work
studying degradation of long-lived proteins in HeLa cells has
established that inhibition of the chymotrypsin-like sites alone is
not sufficient to block protein degradation, and co-inhibition of
either caspase-like and trypsin-like sites is usually needed to
achieve this [17]. The results of the present study confirm this
conclusion. Even in the most sensitive NCI-H929 cell line, only
half of proteasomal proteolysis is inhibited upon 95% inhibition of
chymotrypsin-like activity and 70% inhibition of caspase-like
activity (at 100 nM bortezomib). In RPMI-8226 cells, 95%
inhibition of these two sites and 40% inhibition of trypsin-like
sites are observed upon 64% inhibition of proteasomal proteolysis
(Fig. 3 and Table 1). Thus, inhibition of chymotrypsin-like sites
alone is not sufficient to inhibit protein degradation.
Molecular basis of differences in sensitivity to
bortezomib
The most surprising observation of this study was that similar
inhibition of active sites (by 100 nM bortezomib) causes different
inhibition of protein degradation in different cell lines, and that a
higher concentration of bortezomib is needed to achieve 50%
inhibition of proteasomal proteolysis in less sensitive cell lines.
Although some difference was observed in the recovery of
proteasome activity after removing bortezomib, the differences
in the first hour after withdrawing the drug were much smaller
than the differences in the inhibition of protein degradation. This
observation, together with the correlation between load/capacity
and IC50 is consistent with the hypothesis that the sensitivity of
myeloma cells to bortezomib depends on the ratio of proteasome
load to proteasome capacity [19].
While this manuscript was under review, it was reported that
treatment with a proteasome inhibitor-induced apoptosis is the
consequence of amino acid depletion from culture media of
Drosophila cells, NIH3T3 mouse fibroblasts, human embryonal
kidney 293T and human cervical carcinoma HeLa cells, followed
by stress response and apoptosis [38]. Although the conclusions
about mechanisms of proteasome-inhibitor induced apoptosis in
these non-secretory cells are different from ones obtained in this
study, these discrepancies raise the possibility that proteasome
inhibitors activate different apoptosis mechanisms in non-secretory
cells expected to have lower load on proteasome.
In summary, this study illustrates the importance of using
clinically relevant concentrations and treatment durations of
pharmacologic agents during in vitro experiments. This approach
revealed important insights into the mechanism of differential
sensitivity of myeloma cells to the proteasome inhibitor bortezo-
mib. Using this approach, we discovered that similar inhibition of
active sites across cell lines does not necessarily result in similar
inhibition of protein degradation.
Supporting Information
Table S1 Three washes are sufficient to remove free
[3H]Leu from the cells during pulse-chase experiments.
After pulsing NCI-H929 cells for 1 h with 10 mCi/ml [3H]Leu,
cells were washed four times with media containing 2.56cold Leu,
and amounts of radioactivity in each sample determined on the
scintillation counter.
(DOC)
Table S2 Treatment of cells with proteasome inhibitors
during the 1-h pulse does not affect incorporation of
[3H]Leu. The rates of [3H]Leu incorporation into 10% TCA
insoluble fraction in the presence and absence of inhibitors was
determined as described in Experimental Procedures.
(DOC)
Table S3 Effect of ZL3-ek on proteasome activity. MM
cells were treated with 10 mM ZL3ek for 1 h, and after removal of
the inhibitor proteasome activities were measured with Protea-
some Glo assay as described [17]. Mock-treated cells served as
controls. Values are averages (6 S.E.M) of 2–3 independent
experiments (biological replicates).
(DOC)
Figure S1 Treatment with bortezomib does not up-
regulate proteasome. Cells were treated with bortezomib, and
then cultured in the absence of inhibitors. At times indicated, a
fraction of cells was harvested, and lysed in the whole cell lysis
buffer. A. Western blot analysis using anti-Rpt5, a6, and a5
antibodies (Enzo). The double Rpt5 band most likely is the
consequence of post-translational modification. B. Quantification
of western blots in panel A using Odyssey fluorescent scanner.
Data is mean6S.E.M. of two independent experiments.
(TIF)
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